echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Pfizer's oral new crown drug has a final effective rate of 89% and is effective for the Omi Keron variant

    Pfizer's oral new crown drug has a final effective rate of 89% and is effective for the Omi Keron variant

    • Last Update: 2022-01-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 15th, Pfizer announced its new COVID-19 oral antiviral drug candidate Paxlovid (nirmatrelvir tablets (PF-07321332); ritonavir tablets) for the treatment of non-hospitalized patients with high risk of developing severe diseases in adults with COVID-19 infection The final analysis results of the randomized, double-blind phase II/III EPIC-HR study


    The final analysis results of the study are consistent with the results of the interim analysis announced in November 2021.


    In terms of secondary endpoints, among patients treated within five days of the onset of symptoms, Paxlovid can reduce the risk of COVID-19-related hospitalization or death from any cause by 88% compared with placebo, which is higher than the 85 observed in the interim analysis.


    The SARS-CoV-2 viral load test of 499 patients in the EPIC-HR trial showed that compared with placebo, the viral load on day 5 of the Paxlovid group was reduced by about 10 times compared with the baseline, indicating that Paxlovid is against SARS-CoV-2 has strong activity and is the strongest reduction in viral load among oral COVID-19 preparations reported so far


    Another interim analysis of the Phase II/III study code-named EPIC-SR showed that for unvaccinated adults and vaccinated adults with one or more risk factors for progression to severe disease, Paxlovid did not reach patients A self-reported new primary endpoint of sustained relief of all symptoms for four consecutive days


    The key secondary endpoint showed that compared with placebo, the hospitalization rate of the treated population was reduced by 70%, and there were no deaths


    Recent in vitro data confirmed that nirmatrelvir is an effective inhibitor of Omi Keron 3CL protease


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.